Accessed July 3, 2020. https: //www.biorxiv.org/content/10.1101/ 691469v1. 25. Reuschenbach M, Kloor M, Morak M, Wentzensen N, Germann A, Garbe Y, et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Fam Cancer 2010;9:173 –9. 26. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014;11:509 –24. 27. Bauer K, Nelius N, Reuschenbach M, Koch M, Weitz J, Steinert G, et al. T cell responses against microsatellite instability-induced frameshift peptides and inﬂuence of regulatory T cells in colorectal cancer. Cancer Immunol Immun- other 2013;62:27 –37. 28. Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J 2013;32:194 –203. 29. Westdorp H, Gorris MAJ, Boudewijns S, Bisseling T, de Goede AL, van Rossum MM, et al. Preventive dendritic cell vaccination in healthy lynch syndrome mutation carriers. Ann Oncol 2016;27:1056PD –PD. 30. Westdorp H, Fennemann FL, Weren RD, Bisseling TM, Ligtenberg MJ, Figdor CG, et al. Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother 2016;65:1249 –59. 31. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair de ﬁciency. N Engl J Med 2015;372: 2509 –20. 32. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch- repair de ﬁciency predicts response of solid tumors to PD-1 blockade. Science 2017;357:409 –413.33.